ATE468849T1 - Idebenon zur behandlung von muskeldystrophien - Google Patents

Idebenon zur behandlung von muskeldystrophien

Info

Publication number
ATE468849T1
ATE468849T1 AT06723554T AT06723554T ATE468849T1 AT E468849 T1 ATE468849 T1 AT E468849T1 AT 06723554 T AT06723554 T AT 06723554T AT 06723554 T AT06723554 T AT 06723554T AT E468849 T1 ATE468849 T1 AT E468849T1
Authority
AT
Austria
Prior art keywords
idebenone
treatment
muscle dystrophies
treating
dystrophies
Prior art date
Application number
AT06723554T
Other languages
German (de)
English (en)
Inventor
Thomas Meier
Gunnar Buyse
Original Assignee
Santhera Pharmaceuticals Ch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36572153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE468849(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Santhera Pharmaceuticals Ch filed Critical Santhera Pharmaceuticals Ch
Application granted granted Critical
Publication of ATE468849T1 publication Critical patent/ATE468849T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT06723554T 2005-03-21 2006-03-20 Idebenon zur behandlung von muskeldystrophien ATE468849T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05006137 2005-03-21
PCT/EP2006/002536 WO2006100017A1 (en) 2005-03-21 2006-03-20 Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1 ,4- benzoquinone for the treatment of muscular dystrophies

Publications (1)

Publication Number Publication Date
ATE468849T1 true ATE468849T1 (de) 2010-06-15

Family

ID=36572153

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06723554T ATE468849T1 (de) 2005-03-21 2006-03-20 Idebenon zur behandlung von muskeldystrophien

Country Status (17)

Country Link
US (1) US7977388B2 (enExample)
EP (1) EP1861080B1 (enExample)
JP (1) JP4896123B2 (enExample)
AT (1) ATE468849T1 (enExample)
AU (1) AU2006226623B2 (enExample)
CA (1) CA2602290C (enExample)
CY (1) CY1110182T1 (enExample)
DE (1) DE602006014514D1 (enExample)
DK (1) DK1861080T3 (enExample)
ES (1) ES2345353T3 (enExample)
MX (1) MX2007011571A (enExample)
NZ (1) NZ561235A (enExample)
PL (1) PL1861080T3 (enExample)
PT (1) PT1861080E (enExample)
SI (1) SI1861080T1 (enExample)
WO (1) WO2006100017A1 (enExample)
ZA (1) ZA200707833B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2046348B1 (en) 2006-08-01 2015-07-22 Phrixus Pharmaceuticals, Incorporated Use of poloxamer for the prevention and/or treatment of heart failure
EP1891946A1 (en) * 2006-08-14 2008-02-27 Santhera Pharmaceuticals (Schweiz) AG Transmucosal administration of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone
US8852568B2 (en) 2007-12-17 2014-10-07 The Regents Of The University Of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies
DK2108366T3 (da) * 2008-04-09 2012-01-30 Santhera Pharmaceuticals Ch Idebenon til behandling af respiratorisk sygdom ved muskeldystrofi
EP2246048A1 (en) * 2009-04-30 2010-11-03 Santhera Pharmaceuticals (Schweiz) AG Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis
DK2605769T3 (en) 2010-08-16 2016-10-24 Santhera Pharmaceuticals (Schweiz) Ag Benzoquinonderivater for the treatment of mitochondrial diseases of the eye
CN103086861B (zh) * 2012-11-12 2015-09-16 刘炜 羟癸基苯醌衍生物及其用途
WO2021127003A1 (en) * 2019-12-16 2021-06-24 Children's Medical Center Corporation Treating heart disease in muscular dystrophy patients
WO2022258629A1 (en) 2021-06-07 2022-12-15 Katholieke Universiteit Leuven Idebenone in the treatment of drug resistant epilepsy
CN113827585B (zh) * 2021-10-27 2023-04-11 山东大学齐鲁医院 艾地苯在治疗肢带型肌营养不良2g型中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8562998A (en) 1997-08-12 1999-03-01 Takeda Chemical Industries Ltd. Idebenone-containing preparation for percutaneous administration
JPH11116470A (ja) 1997-08-12 1999-04-27 Takeda Chem Ind Ltd イデベノン含有経皮投与製剤
US20030013772A1 (en) * 2000-02-23 2003-01-16 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
CA2272971C (en) * 1998-10-29 2008-01-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
US20040081961A1 (en) * 2001-05-04 2004-04-29 Delegeane Angelo M Proteases
EP1618881A1 (en) * 2004-07-20 2006-01-25 Santhera Pharmaceuticals (Schweiz) GmbH Use of non-glucocorticoid steroids for the treatment of muscular dystrophy

Also Published As

Publication number Publication date
AU2006226623A1 (en) 2006-09-28
EP1861080A1 (en) 2007-12-05
DK1861080T3 (da) 2010-09-06
JP2008533182A (ja) 2008-08-21
EP1861080B1 (en) 2010-05-26
JP4896123B2 (ja) 2012-03-14
PL1861080T3 (pl) 2010-10-29
NZ561235A (en) 2010-12-24
AU2006226623B2 (en) 2010-04-22
ES2345353T3 (es) 2010-09-21
CA2602290A1 (en) 2006-09-28
SI1861080T1 (sl) 2010-08-31
WO2006100017A1 (en) 2006-09-28
US7977388B2 (en) 2011-07-12
US20090012050A1 (en) 2009-01-08
MX2007011571A (es) 2007-12-06
CY1110182T1 (el) 2015-01-14
DE602006014514D1 (enExample) 2010-07-08
ZA200707833B (en) 2008-06-25
PT1861080E (pt) 2010-06-17
CA2602290C (en) 2012-01-17

Similar Documents

Publication Publication Date Title
CY1110182T1 (el) Ιδεβενονη για τη θεραπεια των μυϊκων δυστροφιων
EA200601776A1 (ru) Метадоновые композиции местного действия и способы их применения
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DE60328476D1 (de) Medizinisches ballonsystem zur behandlung von adipositas
DE60313597D1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
DE602004004331D1 (de) Implantierbare Pumpe zur Behandlung von Fettleibigkeit
EP1991218A4 (en) USE OF CYCLOLIGNANS IN THE TREATMENT OF TYPE 2 DIABETES AND AS CONTRACEPTIVES
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
EA200602047A1 (ru) Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака
ZA200703441B (en) Coadministration of tigecycline and digoxin
EA200970957A1 (ru) Лекарственная комбинация и её применение при лечении атрофии мышечной ткани
EP2716285A3 (en) New method for identifying compounds useful for treating and/or preventing diseases associated with bone loss
DE602004005821D1 (de) Enteralpräparat zur vorbeugung gegen bzw. behandlung von sepsis
WO2004006911A3 (fr) Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
EA201070193A1 (ru) Лечение детских опухолей
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DE602005027251D1 (de) Sulfamide alsendothelinrezeptorantagonsiten zur behandlung von herzkreislauferkrankungen
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
TW200628168A (en) Use of organic compounds
DE10394347T5 (de) Eine synergistische Zusammensetzung zur Behandlung von Hyperlipidämie
DE602006021594D1 (de) Verbindung zur prävention und behandlung von links
DE602005011029D1 (de) Therapeutisches mittel zur behandlung von plasmazellneoplasien
WO2007012066A3 (en) TRUNCATED OXIDIZED THYMOSIN β4 AND DERIVATIVES THEREOF
BRPI0909447A2 (pt) Composição, métodos para tratar um indivíduo humano ou animal em necessidade de tal tratamento e para matar ou inibir o crescimento de microrganismos suscetíveis, e, uso de uma composição

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1861080

Country of ref document: EP